Industry News
Biotechnology Industry News

AstraZeneca isn’t letting a…
AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it
Otsuka Pharmaceutical has acquired…
Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal that could also deliver up to $525 million in milestone payments tied to assets in
Takeda has posted phase 3 data on…
Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share with companies including Bristol Myers Squibb and Johnson &
Merck & Co. has lifted the lid…
Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the cardiovascular disease prospect has over other oral non-statin therapies.
Boehringer Ingelheim may have been…
Boehringer Ingelheim may have been on a spending spree for licensing deals so far this year—but the German pharma has plenty more items on its shopping list.
AstraZeneca’s chronic…
AstraZeneca’s chronic obstructive pulmonary disease drug candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and Sanofi.
Novartis has penned a $2 billion…
Novartis has penned a $2 billion deal for a biotech whose next-gen anti-IgE program could offer a worthy successor to Xolair.
Seasoned biotech takeover titan…
Seasoned biotech takeover titan Kevin Tang has struck again. After serving as board chair of Aurinia since 2024, Tang has now ascended to the CEO spot and swapped out the company’s C-suite with a cadre
Pulmatrix may have been discarded…
Pulmatrix may have been discarded by Cullgen, but the inhaled therapy biotech’s Nasdaq listing has caught the attention of another company.
Oral peptide specialist Pinnacle…
Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million.
John Stanford spent a busy day on…
John Stanford spent a busy day on Capitol Hill this week making the case that the success of the domestic biotech industry is an issue of national security, health care access and economic competitiveness.
Wave Life Sciences linked its…
Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive the stock down by more than 50% despite the biotech hailing the data
Biopharma funding fell 20% last…
Biopharma funding fell 20% last year, reversing the post-pandemic recovery as the IPO haul dropped to the lowest level of the past 10 years, according to an IQVIA analysis.
Innate Pharma has finally called…
Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.
Radioligand therapy has…
Radioligand therapy has irrevocably changed oncology, proving we can map biology and strike cancer cells with unprecedented precision. Research suggests that up to 80% of cancers could potentially be addressed by this approach.
Maze Therapeutics has revealed…
Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” But many investors were racing for the exits Wednesday.
Merck and Terns Pharmaceuticals…
Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the New Jersey Big Pharma.
Sarepta Therapeutics has shared…
Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead Pharmaceuticals’ pipeline.
China’s BrightGene has served up…
China’s BrightGene has served up a slice of early-stage data to remind everyone that it has a horse in the oral obesity race.
Full 12-month data from Ocugen’s…
Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, though the treatment’s smaller effect compared to an earlier preliminary analysis sent the biotech’s stock

